SEP 06, 2012
2012 Annual Scientific Meeting of the American Society of Retina Specialists
Comprehensive Ophthalmology, Retina/Vitreous
Dr. Wiley Chambers, deputy director of ophthalmology products at the FDA, reveals common reasons why certain new drugs are not approved for the market while some established products remain unapproved despite widespread off-label use and proven safety and efficacy. Dr. Chambers presented his insights at the 2012 Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).
Dr. Chambers has no financial interests to disclose.